Maintaining an unbroken cold chain isn’t just a best practice, it’s a non-negotiable regulatory requirement. As we navigate 2025, the stakes are higher than ever for pharmaceutical companies, vaccine manufacturers, research institutions and distributors. The increasing demand for temperature-sensitive biologics and advanced therapies, coupled with evolving global regulations, demands robust cold chain monitoring and compliance
